US › Healthcare

Galectin Therapeutics Inc (GALT)

US · Healthcare · Biotechnology

$3.71+0.82%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-9.1M

EPS

$-0.14

EPS estimate

$-0.09

EPS came in at -0.14 against a street estimate of -0.09 — a miss of 55.6%.

Key statistics

Market cap

$387.3M

Forward P/E

4.5

P/B

207.70

Book value

$-2.10

EPS (TTM)

$-0.43

52-week high

$7.13

52-week low

$2.03

50-day MA

$3.85

200-day MA

$3.41

Beta

0.39

Analyst view

Analysts rate Galectin Therapeutics Inc a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $11.00.

Shareholding

Insiders

53.08%

Institutions

15.65%

Largest institutional holders

Fund	Stake
Vanguard Capital Management, LLC	1.95%
Marshall Wace Asset Management Ltd	1.21%
Advisor Group Holdings, Inc.	1.11%
BlackRock Inc	0.79%
Sontag Advisory LLC	0.72%
Geode Capital Management, LLC	0.61%
Susquehanna International Group, LLP	0.55%
Commonwealth Equity Services, LLC	0.40%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Galectin Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.